NeuroOne Medical Technologies Corporation NMTC 深 沪
交易中 02-04 10:06:20 美东时间
0.86
+0.000
+0.03%
华盛通- 最 高0.86
- 今 开0.86
- 成交量 1.53万股
- 最 低 0.86
- 昨 收 0.8597
- 总市值 4299.96万
- 52周最高 1.25
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 0.3954
- 委 比 -25.00%
- 总股本 4999.95万
- 历史最高 7.97
- 量 比 1.41
- 振 幅 0.00%
- 历史最低 0.3954
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroOne plans 2026 drug delivery commercialization as Q4 product revenue jumps 907%
Earnings Call Insights: NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Management View CEO David Rosa stated that fiscal year 2025 was the most successful in the company's history and an inf...
2025-12-18 00:20
NeuroOne Medical Tech Q4 EPS $(0.04), Inline, Sales $2.741M Beat $2.470M Estimate
NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 63.64 percent increase over losses of $(0.11) per share from the same period last
2025-12-17 19:40
NeuroOne Reports Record Revenue Growth for 2025
NeuroOne Medical Technologies ( ($NMTC) ) has issued an update. On October 6, 2...
2025-10-07 04:51
美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
2025-09-10 18:01
Maxim Group Initiates Coverage On NeuroOne Medical Tech with Buy Rating, Announces Price Target of $3
Maxim Group analyst Anthony Vendetti initiates coverage on NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy rating and announces Price Target of $3.
2025-09-09 22:23
NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
NeuroOne Medical Technologies Corporation will participate in the Sidoti & Co. Virtual Small-Cap Conference on September 17-18, 2025. CEO Dave Rosa and CFO Ron McClurg will present on September 17 at 12:15pm ET and host investor meetings. The company reported a 105% revenue increase to $1.7 million in Q3 2025 and a 53.9% gross margin, along with FDA clearance for its OneRF® system. NeuroOne aims to raise investor awareness and discuss growth oppo...
2025-09-08 20:05
NeuroOne Gains FDA Clearance for Nerve Ablation System
NeuroOne Medical Technologies ( ($NMTC) ) has provided an announcement. On Augu...
2025-08-18 20:58
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies Corporation received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, enabling minimally invasive treatment of trigeminal neuralgia, a chronic pain condition affecting around 150,000 people annually. The system uses targeted radiofrequency energy to ablate trigeminal nerve fibers, offering a safer, more precise alternative to traditional pharmaceutical and surgical treatments. NeuroOne plans a limited c...
2025-08-18 12:30
NeuroOne Updates Prospectus for $6.75 Million Offering
NeuroOne Medical Technologies ( ($NMTC) ) has provided an update. On December 2...
2025-08-16 04:58
NeuroOne Medical Technologies shares are trading lower after the company reported a Q2 sales miss.
NeuroOne Medical Technologies shares are trading lower after the company report...
2025-08-15 01:30
